Atossa Therapeutics, Inc.
ATOS
$2.40
-$0.12-4.57%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.05M | 17.79M | 15.96M | 14.42M | 13.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.25M | 39.60M | 37.14M | 32.86M | 29.99M |
| Operating Income | -39.25M | -39.60M | -37.14M | -32.86M | -29.99M |
| Income Before Tax | -37.71M | -37.64M | -34.77M | -30.18M | -28.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.71 | -37.64 | -34.77 | -30.18 | -28.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.71M | -37.64M | -34.77M | -30.18M | -28.72M |
| EBIT | -39.25M | -39.60M | -37.14M | -32.86M | -29.99M |
| EBITDA | -39.24M | -39.58M | -37.13M | -32.84M | -29.97M |
| EPS Basic | -4.34 | -4.37 | -4.04 | -3.52 | -3.37 |
| Normalized Basic EPS | -2.72 | -2.73 | -2.52 | -2.20 | -1.98 |
| EPS Diluted | -4.34 | -4.37 | -4.04 | -3.52 | -3.37 |
| Normalized Diluted EPS | -2.72 | -2.73 | -2.52 | -2.20 | -1.98 |
| Average Basic Shares Outstanding | 34.75M | 34.47M | 34.47M | 34.30M | 34.07M |
| Average Diluted Shares Outstanding | 34.75M | 34.47M | 34.47M | 34.30M | 34.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |